NEO-201 and IL-15 Combination Therapy: In Vitro and Mouse Model Results

A 14.5 KB document details the results of a preclinical study combining monoclonal antibody NEO-201 with IL-15 against endometrial and ovarian cancer. The research, authored by Jamie Hur and uploaded to figshare in March 2026, demonstrates enhanced antibody-dependent cell-mediated cytotoxicity in vitro and a modest survival benefit in a mouse model. The findings support further investigation into combination therapies for gynecological cancers expressing specific O-glycans.

Use Cases

• Benchmarking in vitro ADCC enhancement results based on the described combination therapy.
• Supporting meta-analyses of preclinical immunotherapy efficacy for gynecological cancers.
• Informing computational models of NK cell activity in the tumor microenvironment described in the study.

Strengths

• Document is licensed under CC-BY-4.0, permitting broad reuse.
• Last updated date is explicitly provided (2026-03-17).

Limitations

• Row count and column-level documentation are absent; data structure must be inferred from the text.
• The 14.5 KB size indicates a very limited scope, likely containing summary results rather than raw experimental data.
• Description metadata is limited; actual data quality requires manual inspection after download.

Provenance

Source

figshare

Collection Method

Likely contains summarized results from in vitro cell line experiments and an in vivo mouse model study.

Freshness

Last updated 2026-03-17 13:06:55; freshness should be verified.